ArticleIJID regions2026
External validation of the MMCD score for renal replacement therapy in two Brazilian cohorts of COVID-19 patients.
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the predictive capacity of the MMCD score for the need for RRT in patients hospitalized with COVID-19. Methods: A retrospective cohort study was conducted at two hospitals in Salvador, Bahia, Brazil, from 2021 to 2022. Clinical data and RRT use were collected from medical records. Predictive performance was evaluated using the area under the receiver operating characteristic curve (AUROC). Results: We analyzed 200 patients (median age, 56 years; 55.0% male). The RRT rate was 14.0% (n = 28). The mean MMCD score was 4.32, indicating a significant association with RRT use ( Conclusion: The MMCD score was a reasonable predictor of the need for RRT in patients with COVID-19. It is a user-friendly tool that can alert professionals to the risk of renal deterioration and guide resource allocation to prevent adverse outcomes. However, its performance should be interpreted with caution given the study's sample size and missing data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.